CVS CEO Karen Lynch Takes over Day-to-Day Management of Aetna
After less than a year, Aetna president Brian Kane is out at CVS Health, it was announced today at an investor call. The change was made to address the continued pressure in the company’s healthcare benefits business.
Brian Kane
Aetna president Brian Kane has left CVS Healthcare, and CEO Karen Lynch will assume direct leadership of the company’s Health Care Benefits segment. The move was made to address the continued pressure in the company’s healthcare benefits business, Lynch said during an investor call this morning.
Kane had joined the company in September 2023.
Karen Lynch
“The majority of our businesses are performing well, and we continue to drive the integrated value of our company by executing on our strategy to connect people to the care and the coverage they need,” she said. “However, we are disappointed by the current performance and outlook for the healthcare benefits segment, and I have decided to make leadership changes effective immediately.”
Although revenue for Aetna and CVS’s healthcare benefits segment for the second quarter of 2024 increased to $32 billion, up 21.4% compared with last year, the medical benefit ratio has also increased— from 82.2% in the second quarter last year to 89.6% this year. The company said this was the result of increased utilization, a decline in star ratings in Medicare plans, higher acuity patients requiring higher levels of care in Medicaid programs, and a change in the risk for the healthcare exchange business.
Thomas F. Cowhey
Thomas F. Cowhey, executive vice president and chief financial officer of CVS Health, said during the investor call that medical cost trend is increasing, and the company may add to medical reserves.
This has led CVS Healthcare to lower its outlook for the remainder of the year. “Full year medical benefit ratio to be in a range of 90.6% to 90.8%,” he said.
“Following the close of the second quarter, we saw indications of potential trend acceleration, which we have contemplated in our revised guidance range,” Lynch said. “We saw an increase in the dislocation between Medicaid acuity level and rate. We will continue working closely with our state partners to advocate for rates that more closely align with changes in acuity within the quarter.”
In addition, CVS Health has announced that Katerina Guerraz, executive vice president and chief strategy officer will be chief perating officer of the Health Care Benefits segment. She is a 20-year Aetna veteran with commercial and Medicare experience.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
A Conversation with Jeremiah Johnson, Executive Director of PrEP4All
July 25th 2025Jeremiah Johnson, executive director of PrEP4All, an organization committed to HIV prevention and care, talks about the importance of preexposure anaphylaxis and why he’s hesitant to jump on the Lenacapavir breakthrough bandwagon.
Read More
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More
